DGCR6L Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of Raji B lymphocytes engineered to harbor a targeted disruption of the DGCR6L gene. This product provides a loss-of-function model within an immune-relevant cellular context, enabling investigation of DGCR6L function in B cells. The polyclonal nature of the knockout population captures a range of genetic edits, making it suitable for pooled screening approaches without the selection bias associated with monoclonal isolates.
The Raji cell line is a well-characterized human B lymphoblastoid line derived from a Burkitt’s lymphoma patient. These cells exhibit mature B cell features, including surface immunoglobulin expression, and are widely utilized in immunology, cancer biology, and virology research. Their robust proliferation and capacity for antigen presentation make them an effective host for studying gene function in lymphocyte biology and hematopoietic malignancies.
DGCR6L resides in the 22q11.2 chromosomal region, a locus critical for normal development and commonly deleted in DiGeorge syndrome and related disorders. The gene is hypothesized to participate in neural crest cell development and craniofacial morphogenesis, potentially through retinoic acid-responsive signaling networks. Upstream regulators such as TBX1 and retinoic acid receptors may modulate DGCR6L expression, while interaction with PCNA, predicted by homology to DGCR6, suggests a possible role in cell cycle or DNA repair processes. Additionally, representative pathway components including FGF8, BMP4, and SHH are implicated in the same developmental cascades, placing DGCR6L within a signaling nexus essential for tissue patterning.
Although DGCR6L??s canonical roles are defined in developmental contexts, its expression in B lymphocytes raises intriguing questions regarding extra-developmental functions. The knockout in Raji cells offers a unique tool to dissect potential gene-dosage effects and non-canonical activities in immune cells. Given the immune deficiencies often observed in 22q11.2 deletion syndromes, this model may illuminate contributions of individual genes to B cell maturation, activation, or homeostasis.
This DGCR6L knockout cell pool is ideal for functional genomics studies, including CRISPR-based genetic screens and transcriptomic profiling via RNA-seq to identify dysregulated pathways. Researchers can validate knockout efficiency through RT-qPCR and western blotting, assess B cell phenotype by flow cytometry for surface markers, and measure functional outcomes such as proliferation and apoptosis. Applications extend to drug target validation for neuropsychiatric disorders linked to 22q11.2 and off-target analysis in B cell lines. For additional technical details, please contact Ascent Research.
